Amber Dance
Freelance science journalist
Freelance science journalist
Amber Dance, Ph.D., an award-winning freelance science journalist based in Southern California, co-authors the Center's Health Divide column. She also contributes to publications including PNAS Front Matter, The Scientist, and Nature. She also edits books on a variety of topics.
After earning a doctorate in biology, Amber Dance re-trained in journalism as a way to engage her broad interest in science and share her enthusiasm with readers. She mainly writes about life sciences, with particular expertise in microbiology, cell biology, neuroscience and lab techniques.
In this week's Coronavirus Files newsletter, eviction moratorium are set to expire; restrictions lift as the virus simmers; delta variant is poised to dominate
For foster kids, lockdown begets 'perhaps irreversible damage;' young people can get seriously ill with COVID; younger kids could be vaccinated in fall; looking forward to back-to-school
Examining LGBTQ pandemic health; labeling coronavirus variants; vaccinating the immunocompromised
Hospital closures worsen disparities during pandemic; it's been a week for the lab-leak theory; do vaccines need a boost?
6/9 Webinar: The vaccine tipping point; Latinos face barriers to vaccine; confusion from new CDC guidelines; virtual learning disastrous for special needs students
May 19 webinar: Policing, Race, and Community Safety One Year After George Floyd; long COVID expected to hit communities of color harder; CDC breaks its conservative streak; journalists covering COVID beyond burned out
Business owners of color less likely to benefit from federal aid, vaccination programs pivot with July 4 hopes, Pfizer vaccines for kids coming
Renters struggle to access aid, at-home COVID tests finally take off, millions miss second shots
Pandemic leaves unrecognized tribes behind, Johnson & Johnson vaccine is back, child care crisis hurts women, communities of color, and vaccine supply starts to overtake demand in the U.S.
No ID, no vaccine, Johnson & Johnson vaccine in limbo, U.K. variant not quite so bad?